How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,634 results for

Insomnia Causes

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Altered nocturnal blood pressure profiles in women with insomnia disorder in the menopausal transition. (PubMed)

regulatory control of BP during sleep in the MT insomnia. The causes and long-term consequences of this altered nocturnal BP profile remain to be determined. (...) Altered nocturnal blood pressure profiles in women with insomnia disorder in the menopausal transition. Insomnia disorder is a risk factor for cardiovascular (CV) pathology. It is unknown whether insomnia that develops in the context of the menopausal transition (MT) impacts the CV system. We assessed nocturnal blood pressure (BP) and heart rate (HR) profiles in women with insomnia disorder in the MT.Twelve women meeting DSM-IV criteria for insomnia in the MT (age, mean ± SD: 50.5 ± 3.6 y

2016 Menopause

102. Insomnia and risk of dementia in older adults: Systematic review and meta-analysis. (PubMed)

Insomnia and risk of dementia in older adults: Systematic review and meta-analysis. There are cross-sectional evidences of an association between sleep disorders and cognitive impairment on older adults. However, there are no consensus by means of longitudinal studies data on the increased risk of developing dementia related to insomnia. We conduct a systematic review and meta-analysis to evaluate the risk of incident all-cause dementia in individuals with insomnia in population-based (...) prospective cohort studies. Five studies of 5.242 retrieved references were included in the meta-analysis. We used the generic inverse variance method with a random effects model to calculate the pooled risk of dementia in older adults with insomnia. We assessed heterogeneity in the meta-analysis by means of the Q-test and I2 index. Study quality was assessed with the Newcastle-Ottawa Scale The results showed that Insomnia was associated with a significant risk of all-cause dementia (RR = 1.53 CI95% (1.07

2016 Journal of psychiatric research

103. Effects of armodafinil and cognitive behavior therapy for insomnia on sleep continuity and daytime sleepiness in cancer survivors. (PubMed)

Effects of armodafinil and cognitive behavior therapy for insomnia on sleep continuity and daytime sleepiness in cancer survivors. This study involves the analysis of a secondary outcome of a trial examining whether cognitive behavior therapy for insomnia (CBT-I), a wake-promoting medication (armodafinil), or both results in greater improvement in prospectively assessed sleep continuity and daytime sleepiness than a placebo-alone group among a heterogeneous group of cancer survivors. Whether (...) or not armodafinil alone, and/or when combined with CBT-I, affected adherence with CBT-I was evaluated.This study is a randomized, placebo-controlled, clinical trial.This study was conducted at two northeastern academic medical centers.Eighty-eight cancer survivors with chronic insomnia were recruited between October 2008 and November 2012. Participants were assigned to one of four conditions: 1) CBT-I and placebo (CBT-I+P); 2) CBT-I and armodafinil (CBT-I + A); 2) armodafinil alone (ARM); or 4) placebo alone

Full Text available with Trip Pro

2016 Sleep medicine

104. Insomnia and Restless Leg Syndrome in Patients Undergoing Chronic Hemodialysis in Rafsanjan Ali Ibn Abitaleb Hospital (PubMed)

Insomnia and Restless Leg Syndrome in Patients Undergoing Chronic Hemodialysis in Rafsanjan Ali Ibn Abitaleb Hospital Sleep is one of the most fundamental human needs; without any doubt sleep is even more essential for sick patients, especially for patients with chronic illnesses. Sleep disturbance may lead to anxiety and reduced quality of life. Restless leg syndrome (RLS) is a sensory-motor disorder accompanied by a strong desire to move the legs or other parts of the body, which can cause (...) sleep disturbance. Its etiology is unknown, but increased urea and creatinine levels before dialysis, iron deficiency due to kidney failure and end-stage renal disease (ESRD) are mentioned as causes.This study is designed to examine the prevalence of insomnia and restless leg syndrome in patients undergoing chronic hemodialysis in Rafsanjan Ali Ibn Abitaleb Hospital.In this study we used two questionnaires to evaluate the presence of RLS and insomnia in ESRD patients who were undergoing hemodialysis

Full Text available with Trip Pro

2016 Nephro-urology monthly

105. Insomnia

or more) Impaired memory, concentration, attention about sleep Daytime , , or malaise Depressed mood, irritability or poor motivation Accidents or errors while working or driving Poor work or school performance s or gastrointestinal upset Frequency At least 3 times weekly Duration Transient Insomnia: <7 days Acute Insomnia: <30 days Chronic Insomnia: 30 days or more Subtypes based on cause Primary Insomnia (no cause): <20% of chronic cases Difficult sleep despite adequate conditions and opportunity (...) No other sleep disorder (e.g. ) Comorbid Insomnia ( ) Insomnia secondary to other cause (medication, medical condition) VIII. Management: Non-Pharmacologic Consider written sleep plan Lifestyle changes See Regular (6 hours before bedtime) Cognitive behavior therapy for Insomnia ( ) Preferred first-line management Combines techniques therapy Paradoxical intention (stay awake to reduce anxiety about not falling asleep) Replace dysfunctional beliefs about sleep (e.g. hours of sleep needed per night

2018 FP Notebook

106. A pilot trial of brief group cognitive-behavioral treatment for insomnia in an adult cancer survivorship program. (PubMed)

completed sleep logs throughout the study and measures of sleep at baseline and week 4.Participants reported experiencing insomnia symptoms an average of 2.4 years, with 89.7% indicating that the cancer experience had caused/exacerbated symptoms. Significant pre/post-intervention group improvements in sleep efficiency (77.3% to 88.5%), sleep quality, and insomnia symptoms were reported (all ps < .01). Less than 1 in 3 had discussed insomnia symptoms with their oncology providers in the prior year.Pilot (...) A pilot trial of brief group cognitive-behavioral treatment for insomnia in an adult cancer survivorship program. Cognitive-behavioral therapy for insomnia (CBT-Insomnia) is effective, yet rarely available for cancer survivors. This is unfortunate because survivors are at elevated risk for insomnia, which is associated with significant health consequences in this already at-risk population. Barriers to delivering CBT-Insomnia in oncology settings include a lack of trained providers, distance

2016 Psycho-oncology

107. BDNF in sleep, insomnia, and sleep deprivation. (PubMed)

BDNF in sleep, insomnia, and sleep deprivation. The protein brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family of growth factors involved in plasticity of neurons in several brain regions. There are numerous evidence that BDNF expression is decreased by experiencing psychological stress and that, accordingly, a lack of neurotrophic support causes major depression. Furthermore, disruption in sleep homeostatic processes results in higher stress vulnerability (...) and is often associated with stress-related mental disorders. Recently, we reported, for the first time, a relationship between BDNF and insomnia and sleep deprivation (SD). Using a biphasic stress model as explanation approach, we discuss here the hypothesis that chronic stress might induce a deregulation of the hypothalamic-pituitary-adrenal system. In the long-term it leads to sleep disturbance and depression as well as decreased BDNF levels, whereas acute stress like SD can be used as therapeutic

2016 Annals of Medicine

108. Magnetic Resonance Spectroscopy in Patients with Insomnia: A Repeated Measurement Study (PubMed)

Magnetic Resonance Spectroscopy in Patients with Insomnia: A Repeated Measurement Study Chronic insomnia is one of the most prevalent central nervous system disorders. It is characterized by increased arousal levels, however, the neurobiological causes and correlates of hyperarousal in insomnia remain to be further determined. In the current study, magnetic resonance spectroscopy was used in the morning and evening in a well-characterized sample of 20 primary insomnia patients (12 females; 8 (...) males; 42.7 ± 13.4 years) and 20 healthy good sleepers (12 females; 8 males; 44.1 ± 10.6 years). The most important inhibitory and excitatory neurotransmitters of the central nervous system, γ-aminobutyric acid (GABA) and glutamate/glutamine (Glx), were assessed in the anterior cingulate cortex (ACC) and dorsolateral prefrontal cortex (DLPFC). The primary hypothesis, a diurnal effect on GABA levels in patients with insomnia, could not be confirmed. Moreover, the current results did not support

Full Text available with Trip Pro

2016 PloS one

109. Insomnia and its associations in patients with recurrent glial neoplasms (PubMed)

Insomnia and its associations in patients with recurrent glial neoplasms Patient with neurological disorders and cancer can develop sleep disturbance, in particular insomnia. Etiology of insomnia is multi-factorial in primary brain tumour patients with possible causes including corticosteroids, psychoactive medications, co-morbid psychiatric/medical conditions, and damage to neuronal tissue.To understand better insomnia in recurrent glioma patients, a single-center retrospective analysis (...) was performed looking at recurrent glioma patients from January 2004 to May 2009. Data was extracted and included demographics, clinical factors, psychoactive medications, and co-morbid symptoms. Presence and absence of insomnia complaints was evaluated with other co-morbidities using Chi square and Wilcoxon analyses. Records from 340 recurrent glioma patients were evaluated and 46.8 % (n = 159) indicated presence of insomnia with 20 % (n = 66) actively using medications for sleep. Use of corticosteroids

Full Text available with Trip Pro

2016 SpringerPlus

110. CBT for insomnia in people with active psychotic symptoms

CBT for insomnia in people with active psychotic symptoms CBT for insomnia in people with active psychotic symptoms Search National Elf Service Search National Elf Service » » » » CBT for insomnia in people with active psychotic symptoms Nov 26 2015 Posted by The Better Sleep Trial (BEST) was designed to determine if the proven efficacy of CBT for insomnia would hold true for adults with a diagnosis of a schizophrenia spectrum disorder . This was a pilot study, comparing 24 people receiving CBT (...) that disturbed and disordered sleep have on mental health, and the common co-morbidity of psychosis with sleep disorders, it seems surprising that no RCTs have been conducted to look at insomnia therapies for people with psychotic disorders. Although the authors conducted what seems to be a limited literature search, only using PubMed and the ISRCTN trial registry, my brief Google Scholar and Medline searches did not spring up any hidden gems. Baglioni & Riemann (2012) provide a brief summary of the mental

Full Text available with Trip Pro

2015 The Mental Elf

111. Effect of Heweianshen Decoction on Orexin-A and Cholecystokinin-8 Expression in Rat Models of Insomnia. (PubMed)

Effect of Heweianshen Decoction on Orexin-A and Cholecystokinin-8 Expression in Rat Models of Insomnia. Objective. To study the effect of Heweianshen decoction (HAD) on orexin-A and cholecystokinin-8 (CCK-8) expression in rat models of insomnia caused by injecting parachlorophenylalanine (PCPA) intraperitoneally. Methods. Fifty male Wistar rats were randomly divided into five groups (10 rats in each group): blank group, model group, and low-, medium-, and high-dose HAD-treated groups. A rat (...) model of insomnia was established by injecting intraperitoneally with PCPA (300 mg/kg body weight). Rats were given normal saline (10 mL/kg) or 5.25, 10.5, and 21 g/kg HAD by intragastric administration once a day for 6 days. After that, the rats were sacrificed to collect the hypothalamus for tests, using radioimmunoassay to detect the expression of orexin-A and CCK-8. Results. Heweianshen decoction reduced the expression of orexin-A and increased the expression of CCK-8 in the hypothalamus of rat

Full Text available with Trip Pro

2016 Evidence-based Complementary and Alternative Medicine (eCAM)

112. Cost-effectiveness of i-Sleep, a guided online CBT intervention, for patients with insomnia in general practice: protocol of a pragmatic randomized controlled trial. (PubMed)

Cost-effectiveness of i-Sleep, a guided online CBT intervention, for patients with insomnia in general practice: protocol of a pragmatic randomized controlled trial. Insomnia is a highly prevalent disorder causing clinically significant distress and impairment. Furthermore, insomnia is associated with high societal and individual costs. Although cognitive behavioural treatment for insomnia (CBT-I) is the preferred treatment, it is not used often. Offering CBT-I in an online format may increase (...) access. Many studies have shown that online CBT for insomnia is effective. However, these studies have all been performed in general population samples recruited through media. This protocol article presents the design of a study aimed at establishing feasibility, effectiveness and cost-effectiveness of a guided online intervention (i-Sleep) for patients suffering from insomnia that seek help from their general practitioner as compared to care-as-usual.In a pragmatic randomized controlled trial

Full Text available with Trip Pro

2016 BMC psychiatry

113. ‘Folk theories’ about the causes of insomnia (PubMed)

‘Folk theories’ about the causes of insomnia The present study investigates 'folk theories' about the causes of insomnia. Participants with insomnia (n = 69) completed a qualitative and quantitative assessment of their folk theories. The qualitative assessment was to speak aloud for 1 minute in response to: 'What do you think causes your insomnia?'. The quantitative assessment involved completing the 'Causal Attributions of My Insomnia Questionnaire' (CAM-I), developed for this study (...) . The three most common folk theories for both the causes of one's own insomnia as well as insomnia in others were 'emotions', 'thinking patterns' and 'sleep-related emotions'. Interventions targeting these factors were also perceived as most likely to be viable treatments. Seventy-five percent of the folk theories of insomnia investigated with the CAM-I were rated as more likely to be alleviated by a psychological versus a biological treatment. The results are consistent with research highlighting

Full Text available with Trip Pro

2013 Cognitive Therapy and Research

114. Adult Primary Insomnia - Diagnosis to Management

that induces awakenings as a result of withdrawal during the sleep period • Smoking cessation aids (nicotine replacement products and bupropion) can cause insomnia sleep consolidation 4 Some insomnia patients spend excessive time in bed trying to attain more sleep. Sleep consol- idation is accomplished by compressing the total time in bed to match the total sleep need of the patient. This improves the sleep efficiency. • Devise a “sleep prescription” with the patient: a fixed bedtime and wake time (...) the causes of insomnia (e.g., “I have a chemical imbalance causing my insomnia”) • Amplifying the consequences (e.g., “I cannot do anything after a bad night’s sleep”) • Performance anxiety and loss of control over ability to sleep (e.g., “I am afraid of losing control over my ability to sleep”) Pharmacologic Pharmacotherapy should be considered an adjunctive therapy to cognitive and behavioural therapies in the comprehensive management of primary insomnia. Principles of Treatment Pharmacotherapy

2010 Toward Optimized Practice

115. Adult Insomnia - Assessment to Diagnosis

patients it is important to note that “late life insomnia” requires specific interventions not addressed in this guideline. 1 Insomnia Insomnia Assessment to Diagnosis 2 (see algorithm on page 15) 1. Acute Insomnia - Identify and address trigger(s) - Consider short-term pharmacotherapy with a sedative to prevent a chronic insomnia (nightly sedation for 4 weeks) Insomnia Screening Questionnaire Page 3 SECONDARY CAUSES OF INSOMNIA M: Mood disorders (MDD/GAD) M: Medical disorders M: Medications. Consider (...) Adult Insomnia - Assessment to Diagnosis 1 Guideline for Adult Introduction Acute Insomnia: 1. Duration of 4 weeks or less. 2,3,4,5 Chronic Insomnia: 2. Duration of 4 weeks or more. 2,3,4,5 Primary Sleep Disorder: 3. A primary or intrinsic sleep disorder is one that arises out of the physiological processes of sleep. Examples of primary sleep disorders are obstructive sleep apnea, restless legs syndrome, periodic limb movement disorder or parasomnias. 2 Secondary Insomnia 4. : Secondary

2010 Toward Optimized Practice

116. [Effectiveness of reslip (doxylamine) in short-term insomnia: multicenter comparative randomized study]. (PubMed)

and regimen.The complete clinical remission of insomnia was achieved in majority of patients in both groups. Indicators of insomnia severity, sleep quality and daytime sleepiness in both groups improved with a high significance. Side effects were mild and in most cases did not result in treatment cessation. No significant differences between the groups in terms of clinical efficacy were found.Short-term doxylamine intake causes significant positive clinical effect in short-term insomnia with satisfactory (...) [Effectiveness of reslip (doxylamine) in short-term insomnia: multicenter comparative randomized study]. Evaluate the efficiency of reslip (doxylamine) in short-term insomnia in comparison with donormyl in multicenter comparative randomized study.The study was conducted in 6 medical centers and included 60 patients aged from 30 to 59 years with short-term insomnia. Patients were divided into two groups: in first one patients took reslip and in the second one donormyl in same dosage

Full Text available with Trip Pro

2017 Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

117. The Association between Insomnia and Prescription Opioid Use: Results from a Community Sample in Northeast Florida (PubMed)

The Association between Insomnia and Prescription Opioid Use: Results from a Community Sample in Northeast Florida The current analysis examines whether opioid use is associated with insomnia in a community sample, as the consequences of the growing epidemic of prescription opioid use continue to cause public health concern.A cross-sectional study including 8433 members in a community outreach program, HealthStreet, in Northeast Florida.Community Health Workers (CHWs) assessed health (...) information, including use of opioids (i.e., Vicodin®, Oxycodone, Codeine, Demerol®, Morphine, Percocet®, Darvon®, Hydrocodone) from community members during field outreach. Insomnia was determined based on self-report: "Have you ever been told you had, or have you ever had a problem with insomnia?" Summary descriptive statistics were calculated and logistic regression modeling was used to calculate adjusted odds ratios (ORs) with 95% confidence intervals for insomnia, by opioid use status, after

Full Text available with Trip Pro

2017 Sleep health

118. Letermovir (Prevymis) - to prevent illness caused by cytomegalovirus (CMV) in adults having an allogeneic haematopoietic stem cell transplant

Letermovir (Prevymis) - to prevent illness caused by cytomegalovirus (CMV) in adults having an allogeneic haematopoietic stem cell transplant 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 9 November 2017 EMA/CHMP/490007/2017 (...) population being CMV-seropositive in most countries. Similar to other herpesviruses, acute infection is generally followed by latent (dormant) infection. Among individuals with intact immune systems, reactivation of CMV infection is uncommon and is generally asymptomatic. However, CMV reactivation in immunocompromised patients, such as transplant recipients, can cause significant morbidity and mortality. Annually, approximately 27,000 allogeneic HSCTs are performed worldwide (Gratwohl 2015): in 2014

2018 European Medicines Agency - EPARs

119. Insomnia

or gastroesophageal reflux disease. Drugs and substance abuse such as excessive alcohol intake. Medications such as methylphenidate. Insomnia may be associated with stress, psychiatric comorbidities, medical comorbidities, drug and substance misuse, or current medication (secondary insomnia). However, in up to 20% of people with persistent insomnia, there is no associated cause or comorbidity (primary insomnia). A sleep diary can help identify how much someone is actually sleeping each night, and any factors (...) be required if a primary sleep disorder is suspected, there is doubt regarding the diagnosis, or long-term insomnia has not responded to management in primary care. Have I got the right topic? Have I got the right topic? From age 16 years onwards. This CKS topic covers the management of insomnia in primary care. This CKS topic does not cover the management of underlying causes of insomnia or the management of sleep-related breathing disorders (such as sleep apnoea), circadian rhythm disorders

2014 NICE Clinical Knowledge Summaries

120. Cathy A Alessi and Michael V Vitiello: Cognitive behavioral therapy for insomnia

Cathy A Alessi and Michael V Vitiello: Cognitive behavioral therapy for insomnia Cathy A Alessi and Michael V Vitiello: Cognitive behavioral therapy for insomnia - The BMJ ---> This blog is part of a series of blogs linked with , a database of systematic overviews of the best available evidence on the effectiveness of commonly used interventions. has been consistently demonstrated to be efficacious in a wide variety of settings and patient populations including older adults and settings (...) . This efficacy has been demonstrated in both patients with uncomplicated insomnia and in those whose insomnia is comorbid with a variety of medical and psychiatric conditions including: chronic pain, breast cancer, chronic obstructive pulmonary disease, coronary artery disease, osteoarthritis, fibromyalgia, Alzheimer’s disease, depression, alcohol abuse, and post traumatic stress disorder. Additional randomized clinical trials of CBT-I are being conducted in numerous other patient populations, including

2015 The BMJ Blog

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>